Основная статистика
| CIK | 1844392 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Marpai, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 MARPAI, INC. (Exact N |
|
| August 13, 2025 |
Exhibit 99.1 MARPAI reports Second QUARTER 2025 financial results Marpai Slashes Losses by Two-Thirds in Q2 2025, Paving the Way to Profitability. Operating Expenses Cut 70% as Turnaround Gains Traction Tampa, August 13, 2025, Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced second qu |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| August 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 29, 2025, between Marpai, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| July 21, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 17, 2025, between Marpai, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the Appropriate Box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the Appropriate Box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 MARPAI, INC. (Exact |
|
| May 14, 2025 |
MARPAI reports First QUARTER 2025 financial results Marpai’s turnaround momentum is building. Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI reports First QUARTER 2025 financial results Marpai’s turnaround momentum is building. Tampa, May 14, 2025, Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, announced financial results for the first quarter of 2025. The Company expects to hold a webcast to di |
|
| May 14, 2025 |
Form of Securities Purchase Agreement, dated May 13, 2025 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 13, 2025, between Marpai, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth i |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 13, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI hires dallas scrip as chief operating officer Marpai Bolsters Leadership Team to Drive Profitable High-Growth Strategy with Key Executive Appointment Tampa, May 13, 2025, Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a leader in innovative healthcare technology and Third-Party Administration (TPA) services, today announced a significant addition |
|
| May 13, 2025 |
Offer Letter, dated May 1, 2025, by and between Marpai, Inc. and Dallas Scrip Exhibit 10.1 May 1, 2025 Dallas Scrip 16313 Gulf Blvd. Redington Beach, FL 33708 Re: REVISED Letter of Offer – Dallas Scrip Via Email: [email protected] Dear Dallas, On behalf of Marpai Administrators (Marpai), I am pleased to extend this offer of employment. Your approach, experience, and track record of success are welcome additions. This letter includes the key elements of our employment offer |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40904 MARPAI INC. (Exact |
|
| March 27, 2025 |
MARPAI reports FOURTH QUARTER AND FULL YEAR 2024 financial results Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI reports FOURTH QUARTER AND FULL YEAR 2024 financial results MARPAI exhibits strong, ongoing financial improvement Tampa, March 26, 2025, Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market b |
|
| March 27, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 27, 2025 |
Marpai, Inc. Insider Trading Policy, adopted March 25, 2025. Exhibit 19.1 MARPAI, INC. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: March 25, 2025 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related persons of Marpai, Inc., a Delaware corporation (the “Company”), with respect to transactions in the Company’s securities. The Company has ad |
|
| February 6, 2025 |
Debt Reduction Agreement, dated January 31, 2025, by and among Marpai, Inc. and AXA S.A. Exhibit 10.1 Execution Version Confidential Debt Reduction Agreement This Agreement dated 31 January 2025, is made and entered into by and between Marpai, Inc., a New York corporation (the “Purchaser”) and AXA S.A., a French société anonyme (the “Debt Seller”). The Purchaser and the Debt Seller are referred to herein individually as a “Party” and collectively as the “Parties”. WHEREAS: (A) The Deb |
|
| February 6, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2025 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 6, 2025 |
Exhibit 10.1 AMENDMENT AGREEMENT This Amendment Agreement (“Agreement”), dated as of December 30, 2024, is made by and among JGB Capital L.P., JGB Partners L.P. and JGB (Cayman) Gasconne Ltd. (collectively, the “Purchasers” and each a “Purchaser”), Marpai Inc., a Delaware corporation (the “Company”), JGB Collateral LLC, a Delaware limited liability company (the “Agent”), as agent for the Purchaser |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 30, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 6, 2025 |
Exhibit 4.1 FORM OF AMENDMENT TO SENIOR SECURED CONVERTIBLE DEBENTURE DUE APRIL 15, 2027 This Amendment to the SENIOR SECURED CONVERTIBLE DEBENTURE DUE APRIL 15, 2027 (this “Amendment”), dated December 30, 2024, is made by and between Marpai Inc., a Delaware corporation (the “Company”) and [] (“Holder”). WHEREAS, on April 15, 2024, the Company executed and delivered to Holder a certain Senior Secu |
|
| January 6, 2025 |
MARPAI ANNOUNCES Second Tranche of non-dilutive Growth Funding with UP TO $5 million from JGB Exhibit 99.1 MARPAI ANNOUNCES Second Tranche of non-dilutive Growth Funding with UP TO $5 million from JGB Tampa, January 6, 2025, Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare s |
|
| December 27, 2024 |
Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 December 27, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Marpai, Inc. (CIK: 0001844392) Registration Statement No. 333-284019 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Marpai, Inc. (the “Registrant”) hereby requests acceleration |
|
| December 23, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Marpai Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit (1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.0001 par value per share (2 |
|
| December 23, 2024 |
As filed with the Securities and Exchange Commission on December 23, 2024 As filed with the Securities and Exchange Commission on December 23, 2024 Registration No. |
|
| December 10, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 5, 2024, between Marpai, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set for |
|
| December 10, 2024 |
MARPAI ANNOUNCES PRICING OF $700,000 PRIVATE PLACEMENT Exhibit 99.1 MARPAI ANNOUNCES PRICING OF $700,000 PRIVATE PLACEMENT TAMPA, Fla, Dec. 5, 2024—Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare solutions to self-funded employer healt |
|
| December 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| December 9, 2024 |
MRAI / Marpai, Inc. / EITAN YARON - AMENDMENT NO. 4 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Yaron Eitan c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 (855) 389-7330 (Name, Address and Telephone |
|
| November 12, 2024 |
MARPAI reports Third QUARTER 2024 financial results Turnaround continues to gain traction Exhibit 99.1 MARPAI reports Third QUARTER 2024 financial results Turnaround continues to gain traction Tampa, November 11, 2024, Marpai, Inc. (“Marpai” or the “Company”) (OTCQX: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, healthcare sol |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 MARPAI, INC. (Ex |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| September 4, 2024 |
MRAI / Marpai, Inc. / Lamendola Damien - AMENDMENT NO. 9 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 9) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 (646) 303-3483 (Name, Address and Teleph |
|
| September 3, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 28, 2024, between Marpai, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 7, 2024 |
Exhibit 99.1 MARPAI reports Second QUARTER 2024 financial results Company continues to drive towards profitability Tampa, August 7, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), a technology platform company, which operates as a national Third-Party Administrator (TPA) through its subsidiaries and is transforming the $22 billion TPA market by offering affordable, intelligent, heal |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 MARPAI, INC. (Exact N |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2024 (June 21, 2024) MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 10, 2024 |
Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 June 10, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Marpai, Inc. (CIK: 0001844392) Registration Statement No. 333-279836 on Form S-1 (the “Registration Statement”) Ladies and Gentlemen: Marpai, Inc. (the “Registrant”) hereby requests acceleration of |
|
| May 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Marpai, Inc. (Exact Name of Registrant as Specified in its Charter) Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share (1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, $0.0001 par value per share |
|
| May 30, 2024 |
As filed with the Securities and Exchange Commission on May 30, 2024 As filed with the Securities and Exchange Commission on May 30, 2024 Registration No. |
|
| May 29, 2024 |
MRAI / Marpai, Inc. / Lamendola Damien - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 (855) 389-7330 (Name, Address and Teleph |
|
| May 29, 2024 |
MRAI / Marpai, Inc. / EITAN YARON - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Yaron Eitan c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 (855) 389-7330 (Name, Address and Telephone N |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 24, 2024 |
EXH 99.1 FOR IMMEDIATE RELEASE MARPAI announces withdrawal from nasdaq HEARINGS process and will transition Trading to the otcQX Market Move reduces cost and burdens of Nasdaq listing Tampa, May 24, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer h |
|
| May 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Marpai, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be |
|
| May 22, 2024 |
As filed with the Securities and Exchange Commission on May 22, 2024 As filed with the Securities and Exchange Commission on May 22, 2024 Registration No. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 “ MARPAI, INC. (Exac |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 9, 2024 |
EXH99.1 FOR IMMEDIATE RELEASE MARPAI reports FIRST QUARTER 2024 financial results Reduces Operating Expense by over $5 million and Net Loss by over 50% compared to 2023 Tampa, May 9, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| April 17, 2024 |
EXH 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 15, 2024, between Marpai Inc., a Delaware corporation (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”), and JGB Collateral LLC, a Delaware limited liability company, a |
|
| April 17, 2024 |
Exh 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 15, 2024, between Marpai Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase Agreement, dat |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 17, 2024 |
EXH 10.3 SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of April 15, 2024 (this “Agreement”), is among Marpai Inc., a Delaware corporation (the “Company”), the Subsidiaries of the Company party hereto (such subsidiaries, the “Guarantors” and together with the Company, the “Debtors”) and the holders of the Company’s Senior Secured Convertible Debentures Due April 15, 2027, in the original agg |
|
| April 17, 2024 |
Exh 4.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| April 17, 2024 |
EXH 10.4 GUARANTY THIS GUARANTY (as amended, restated, supplemented or otherwise modified from time to time in accordance with the provisions hereof, this “Guaranty”), dated as of April 15, 2024, is made by each of the undersigned guarantors (collectively, the “Guarantor”) in favor of JGB Collateral LLC, a Delaware limited liability company, in its capacity as agent for the Holders (as defined bel |
|
| March 26, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 26, 2024 |
Marpai Inc. Clawback Policy, dated October 2, 2023. EXH 97.1 Marpai, Inc. Clawback Policy Effective as of October 2, 2023 CLAWBACK POLICY 1.Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to the Company in accordance with the Clawback Rules. 2.Administration. Except as specifically set forth herein, this Policy shall be administered |
|
| March 26, 2024 |
Exhibit 4.4 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 26, 2024, Marpai, Inc., a Delaware corporation (“we,” “our” and the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: Class A Common Stock, par value $0.0001 per share. The following description of such secur |
|
| March 26, 2024 |
EXH 99.1 FOR IMMEDIATE RELEASE MARPAI reports FOURTH QUARTER AND FULL YEAR 2023 financial results Full Year Benefit of Maestro Acquisition and Q4 Corrective Actions Driving Financial Improvement Tampa, March 26, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-fund |
|
| March 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40904 |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the Appropriate Box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the Appropriate Box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 13, 2024 |
nasdaq panel grants marpai’s request for extension to comply with continued listing requirements EXH 99.1 FOR IMMEDIATE RELEASE nasdaq panel grants marpai’s request for extension to comply with continued listing requirements Tampa, March 13, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans with affordable, intelligent, healthcare, |
|
| March 11, 2024 |
MRAI / Marpai, Inc. / Lamendola Damien - SC 13D/A Activist Investment SC 13D/A 1 damien13da3724.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 ( |
|
| March 8, 2024 |
EXH 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 7, 2024, between Marpai, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in t |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 6, 2024 |
EXH 99.1 FOR IMMEDIATE RELEASE MARPAI ANNOUNCES PRELIMINARY UNAUDITED FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2023 Full Year Impact of Maestro Acquisition and Q4 Corrective Actions Driving Improvement Tampa, March 6, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supp |
|
| March 6, 2024 |
EXH 99.1 FOR IMMEDIATE RELEASE MARPAI ANNOUNCES PRELIMINARY UNAUDITED FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2023 Full Year Impact of Maestro Acquisition and Q4 Corrective Actions Driving Improvement Tampa, March 6, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration (TPA) company transforming the $22 billion TPA market supp |
|
| March 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 05, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| March 5, 2024 |
EXH 99.1 FOR IMMEDIATE RELEASE MARPAI ANNOUNCES “Off-cycle” new client agreement Marpai executes new client agreement furthering its expansion in the Southeast. Tampa, March 5, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration (“TPA”) company transforming the $22 billion TPA market supporting self-funded employer health plans with aff |
|
| February 13, 2024 |
SC 13G/A 1 mrai-sc13ga123123.htm AMENDMENT TO FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Marpai, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 571354208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Stat |
|
| February 8, 2024 |
LIBERTAS Libertas Funding, LLC 411 West Putnam Ave Suite 220, Greenwich, CT 06380 AGREEMENT OF SALE OF FUTURE RECEIPTS This AGREEMENT OF SALE OF FUTURE RECEIVABLES (this "Agreement") dated as of 02/02/2024, is made by and between Libertas Funding, LLC, a Connecticut Limited Liability Company as purchaser ("Purchaser"), the merchant whose name, address and other pertinent information is set forth below, as seller ("Merchant"), and the individual owner/guarantor of the Merchant whose name, address and other pertinent information are set forth below ("Guarantor"). |
|
| February 8, 2024 |
Exh 10.2 AMENDMENT NO. 1 TO PURCHASE AGREEMENT This AMENDMENT NO. 1 TO PURCHASE AGREEMENT (this “Amendment”), dated as of February 7, 2024, is made and entered into by and between Marpai, Inc., a New York corporation (“Marpai”) and AXA S.A., a French société anonyme (“AXA”). Marpai and AXA are sometimes individually referred to herein as a “Party” and collectively as the “Parties.” Capitalized ter |
|
| February 8, 2024 |
Exh 99.1 FOR IMMEDIATE RELEASE MARPAI ANNOUNCES KEY FINANCIAL AGREEMENTS Marpai executes amendment with AXA delaying payment obligations and secures $1.7 million in revenue-based financing from Libertas Funding, LLC. New York, February 8, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration company transforming the $22 billion TPA market |
|
| February 8, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| January 19, 2024 |
MRAI / Marpai, Inc. / Lamendola Damien - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 (646) 303-3483 (Name, Address and Teleph |
|
| January 19, 2024 |
MRAI / Marpai, Inc. / EITAN YARON - SC 13D/A Activist Investment SC 13D/A 1 yaron13d1.16.24.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Yaron Eitan c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 (646) |
|
| January 18, 2024 |
EXH 10.5 CONSULTING AGREEMENT This Consulting Agreement (“Agreement”) is entered into as of February 1, 2024 (the “Effective Date”), between Marpai Inc., a Delaware corporation (“Company”), and Gonen Antebi, an individual residing in New Jersey (“Consultant”). Company and Consultant desire to have Consultant perform services for Company, subject to and in accordance with the terms and conditions o |
|
| January 18, 2024 |
EXH 10.2 MARPAI INC. EXECUTIVE EMPLOYMENT AGREEMENT (Damien Lamendola) This Executive Employment Agreement (this “Agreement”) is entered into as of January 2, 2024 between Marpai Inc. a Delaware corporation (the “Company”), and Damien Lamendola (“Executive”). The Company and Executive agree as follows: 1. Employment. Executive’s employment under this Agreement will commence on January 2, 2024 (the |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 18, 2024 |
EXH 10.1 MARPAI INC. EXECUTIVE EMPLOYMENT AGREEMENT (John Powers) This Executive Employment Agreement (this “Agreement”) is entered into as of January 2, 2024 between Marpai Inc. a Delaware corporation (the “Company”), and John Powers (“Executive”). The Company and Executive agree as follows: 1. Employment. Executive’s employment under this Agreement will commence on January 2, 2024 (the “Start Da |
|
| January 18, 2024 |
EXH 10.4 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (this "Agreement") is entered into between Marpai, Inc. (together with its existing and future direct and indirect subsidiaries and controlled affiliates, the "Company"), and Gonen Antebi ("Executive") (each individually, a "Party," and collectively, the "Parties"). This Agreement takes effect on the Ef |
|
| January 18, 2024 |
EXH 99.1 FOR IMMEDIATE RELEASE MARPAI HIRES JOHN POWERS AS PRESIDENT Accomplished Industry Veteran with Proven Track Record of Successful High Growth Operations to support Marpai’s vision of Affordable, Intelligent, Healthcare New York, January 11, 2024, Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administration company transforming the $22 billion |
|
| January 18, 2024 |
EXH 10.3 MARPAI INC. EXECUTIVE EMPLOYMENT AGREEMENT (Steve Johnson) This Executive Employment Agreement (this “Agreement”) is entered into as of January 2, 2024 between Marpai Inc. a Delaware corporation (the “Company”), and Steve Johnson (“Executive”). The Company and Executive agree as follows: 1. Employment. Executive’s employment under this Agreement will commence on January 2, 2024 (the “Star |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 17, 2024 |
SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 16, 2024, between Marpai, Inc. |
|
| December 18, 2023 |
MRAI / Marpai, Inc. / Lamendola Damien - SC 13D/A Activist Investment SC 13D/A 1 copyofdamien13da1214.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 3 |
|
| December 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 15, 2023 |
EXH 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 14, 2023, between Marpai, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 13, 2023 |
MARPAI, INC. ANNOUNCES APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS EXH 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. ANNOUNCES APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS New York, December 13, 2023 Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administrator (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans, today announced the addition of two new members to its Board of Di |
|
| December 11, 2023 |
Separation Agreement, executed by and between Marpai, Inc. and Yoram Bibring, dated December 5, 2023 EXH 10.2 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (this “Agreement”) is entered into between Marpai, Inc. (together with its existing and future direct and indirect subsidiaries and controlled affiliates, the “Company”), and Yoram Bibring (“Executive”) (each individually, a “Party,” and collectively, the “Parties”), as of the Effective Date (as defined |
|
| December 11, 2023 |
EXH 1.1 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 4 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUAN |
|
| December 11, 2023 |
EXH 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (this "Agreement") is entered into between Marpai, Inc. (together with its existing and future direct and indirect subsidiaries and controlled affiliates, the "Company"), and Edmundo Gonzalez ("Executive") (each individually, a "Party," and collectively, the "Parties"). This Agreement takes effect on th |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| December 6, 2023 |
MARPAI, INC. REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE COMPLIANCE EXH 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE COMPLIANCE New York, December 6, 2023 Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an independent national Third-Party Administrator (TPA) company transforming the $22 billion TPA market supporting self-funded employer health plans, today announced that the Company received a notification lette |
|
| December 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 29, 2023 |
| MarpaiHealth.com (NASDAQ: MRAI) Investor Webcast November 2023 EXH 99.1 | MarpaiHealth.com (NASDAQ: MRAI) Investor Webcast November 2023 EXH 99.1 | 2 Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended. S |
|
| November 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 28, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 28, 2023 |
MRAI / Marpai Inc Class A / Lamendola Damien - SC 13D/A Activist Investment SC 13D/A 1 damien13da112223.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 |
|
| November 24, 2023 |
MRAI / Marpai Inc Class A / EITAN YARON - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Yaron Eitan c/o Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 (646) 303-3483 (Name, Address and Telephone N |
|
| November 13, 2023 |
MARPAI, INC. REPORTS Third QUARTER 2023 RESULTS EXH 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS Third QUARTER 2023 RESULTS • Continued year over year growth related to our acquisition of Maestro Health • Further identification and implementation of synergies and opportunities continue as a result of the acquisition • Veteran industry executive leadership announced along with the addition of a seasoned health care leader to strengthen the Bo |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 “ MARPAI, INC. ( |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 9, 2023 |
EXH 99.1 Marpai Names Damien Lamendola as Chief Executive Officer to Drive the Next Phase of its Growth Healthcare Industry Luminary is also the Company’s Largest Shareholder NEW YORK, November 6, 2023 /PRNewswire/ - Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), a full-service Third-Party Administrator (TPA) specializing in cost management through intelligent processes and systems, is e |
|
| November 9, 2023 |
Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 Marpai, Inc. 615 Channelside Drive, Suite 207 Tampa, Florida 33602 November 9, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Marpai, Inc. (CIK: 0001844392) Withdrawal of Registration Statement on Form S-1, as amended (File No. 333-274162) Ladies and Gentlemen: Pursuant to Rule 477 unde |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 6, 2023 |
MARPAI Proprietary and Confidential. © Marpai, Inc. 2023 | MarpaiHealth.com (NASDAQ: MRAI) Company Presentation Filed pursuant to Rule 433 Issuer Free Writing Prospectus Dated October 6, 2023 Relating to Preliminary Prospectus filed October 6, 2023 Registration No. 333-274162 | October 2023 Free Writing Prospectus Marpai Inc. This presentation highlights basic information about us and the proposed |
|
| October 6, 2023 |
Table of Contents Index to Financial Statements As filed with the Securities and Exchange Commission on October 6, 2023 Registration Statement No 333-274162 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 6, 2023 |
Exhibit 4.69 PRE-FUNDED COMMON STOCK PURCHASE WARRANT MARPAI, INC. Warrant Shares: Issue Date: , 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and |
|
| October 6, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1/A (Form Type) Marpai, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee (6) Fees to be paid Equity Class A Com |
|
| October 6, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 06, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 6, 2023 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between MARPAI, INC. and THINKEQUITY LLC as Representative of the Several Underwriters MARPAI, INC. UNDERWRITING AGREEMENT New York, New York [•], 2023 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 22nd Fl New York, NY 10004 Ladies and Gentlemen: The undersigned, Marpai, Inc., a corporation form |
|
| October 6, 2023 |
Form of Representative’s Warrant Exhibit 4.2 EXHIBIT B Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HU |
|
| August 23, 2023 |
Exhibit 10.38 ADVISORY AGREEMENTS This Advisory Agreement (this “Agreement”) is entered into as of August 16, 2023 (“Effective Date”), between Lutz Finger, an individual (“Advisor”) and Marpai, Inc., a Delaware corporation (the “Company”). The parties agree as follows: 1. SCOPE OF SERVICES 1.1 The Company hereby retains the Advisor as a senior advisor to the Company. The Advisor will provide such |
|
| August 23, 2023 |
Exhibit 10.37 MARPAI, INC. Effective date: August 15, 2023 Via Electronic Mail Lutz Finger Re: Employment Termination Agreement Dear Lutz: You and Marpai, Inc. (the “Company”) are parties to an employment agreement dated January 1, 2022 (as amended to date, the “Employment Agreement”), and a Confidentiality and Intellectual Property Assignment Agreement dated as of January 21, 2022 (the “Confident |
|
| August 23, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Marpai, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Fees to be paid Equity Class A Common St |
|
| August 23, 2023 |
Power of Attorney (included on the signature page of this registration statement) S-1 Table of Contents As filed with the Securities and Exchange Commission on August 23, 2023 Registration Statement No 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 17, 2023 |
Consulting Agreement, executed by and between Marpai, Inc. and Lutz Finger, dated August 16, 2023 Exhibit 10.2 ADVISORY AGREEMENTS This Advisory Agreement (this “Agreement”) is entered into as of August 16, 2023 ( “Effective Date”), between Lutz Finger, an individual (“Advisor”) and Marpai, Inc., a Delaware corporation (the “Company”). The parties agree as follows: 1. SCOPE OF SERVICES 1.1 The Company hereby retains the Advisor as a senior advisor to the Company. The Advisor will provide such |
|
| August 17, 2023 |
Separation Agreement, executed by and between Marpai, Inc. and Lutz Finger, dated August 16, 2023 Exhibit 10.1 Marpai, Inc. Effective date: August 15, 2023 Via Electronic Mail Lutz Finger Re: Employment Termination Agreement Dear Lutz: You and Marpai, Inc. (the “Company”) are parties to an employment agreement dated January 1, 2022 (as amended to date, the “Employment Agreement”), and a Confidentiality and Intellectual Property Assignment Agreement dated as of January 21, 2022 (the “Confidenti |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 “ MARPAI, INC. (Exact |
|
| August 3, 2023 |
Exhibit 10.1 July 11, 2023 Mr. Yaron Eitan 188 Ludlow Street Appt 4i New York, NY 10002 Via Email: [email protected] Dear Mr. Eitan, This letter includes the key elements of our compensation arrangement with you. After you carefully review the content, please indicate your acceptance by signing and dating below, and returning this letter no later than July 14, 2023. Title: Chairman of the Board St |
|
| August 3, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 03, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| August 3, 2023 |
Exhibit 10.2 MARPAI, INC. July 31, 2023 Via e-mail Mr. Lutz Finger Dear Lutz, You and Marpai, Inc. (the “Company”) are parties to an employment letter agreement effective February 28, 2022, as amended by the letter agreement effective February 27, 2023 (as so amended, the “Employment Agreement”). This letter (this “Amendment”) modifies the Employment Agreement as set forth below: In Section 10(a), |
|
| August 3, 2023 |
MARPAI, INC. REPORTS SECOND QUARTER 2023 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS SECOND QUARTER 2023 RESULTS New York, August 3, 2023—Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), a technology company transforming the $22 billion Third-Party Administrator (TPA) market supporting self-funded employer health plans, today reported financial results for the second quarter ended June 30, 2023. The Company’s consolid |
|
| July 27, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| July 27, 2023 |
Marpai, Inc. 5701 East Hillsborough Avenue, Suite 141 Tampa, FL 33610 Marpai, Inc. 5701 East Hillsborough Avenue, Suite 141 Tampa, FL 33610 July 27, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549 Re: Marpai, Inc. Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 29, 2023 File No. 001-40904 Ladies and Gentlemen: We are submitting thi |
|
| July 27, 2023 |
List of Subsidiaries of the Company Exhibit 21.1 LIST OF SUBSIDIARIES Company Name Jurisdiction of Incorporation Ownership Marpai Captive, Inc. Delaware 100% Marpai Administrators, LLC Florida 100% Marpai Health, Inc. Delaware 100% EYME Technologies, Ltd. Israel 100% Maestro Health, LLC Delaware 100% |
|
| July 27, 2023 |
Exhibit 10.31 MARPAI, INC. February 23, 2023 Mr. Lutz Finger VIA E-MAIL Dear Lutz: 1. You and Marpai, Inc. (the “Company”) are parties to an Employment Letter Agreement effective February 28, 2022 (the “Employment Agreement”). This letter (this “Amendment”) modifies the Employment Agreement as set forth below: 1.1 Section 10(a) is deleted in its original form and is replaced by the following sente |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 30, 2023 |
Marpai Confirms Revenue Guidance for Q2 2023 of $9.5 Million to $9.8 Million Marpai Confirms Revenue Guidance for Q2 2023 of $9.5 Million to $9.8 Million Company cites expected improvements in EBITDA NEW YORK—(BUSINESS WIRE)—Marpai, Inc.—June 29, 2023—("Marpai" or the "Company") (Nasdaq: MRAI), an AI-powered Third-Party Administrator (TPA) transforming self-funded employer health plans, confirmed its revenue guidance for Q2 2023 as between $9.5 million to $9.8 million. The |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 29, 2023 |
Marpai Announces Reverse Stock Split Marpai Announces Reverse Stock Split NEW YORK-(BUSINESS WIRE)—June 28, 2023 - Marpai, Inc. |
|
| June 29, 2023 |
CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF MARPAI, INC. Marpai, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: FIRST: The name of the Corporation is Marpai, Inc. SECOND: This certificate of amendment (this “Certificate of Amendment”) amends the provisions of the C |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 5, 2023 |
DEF 14A 1 d831602ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the Appropriate Box: ☐ Preliminary Proxy Statement ☐ Confident |
|
| June 2, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 1, 2023 |
Marpai Launches Marpai Connect Platform to Predict and Help Modify Risk in Healthcare Marpai Launches Marpai Connect Platform to Predict and Help Modify Risk in Healthcare Marpai Connect proactively matches members to best-in-class value-based providers to improve member health and lower costs for employers NEW YORK-(BUSINESS WIRE)- Marpai, Inc. |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| June 1, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 26, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 “ MARPAI, INC. (Exac |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| May 10, 2023 |
MARPAI, INC. REPORTS FIRST QUARTER 2023 RESULTS FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS FIRST QUARTER 2023 RESULTS New York, May 10, 2023—Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), a technology company transforming the $22 billion Third-Party Administrator (TPA) market supporting self-funded employer health plans, today reported financial results for the first quarter ended March 31, 2023. The Company’s consolidated results of |
|
| April 26, 2023 |
Altium Capital Management, LP SC 13G Page 9 of 9 EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Marpai, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 571354109 (CUSIP Number) April 17, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| April 19, 2023 |
Marpai, Inc. Announces Pricing of Public Offering Exhibit 99.2 Marpai, Inc. Announces Pricing of Public Offering New York – April 17, 2023 – Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI) a technology company using artificial intelligence (A.I.) to transform health plans for employers that self-fund their healthcare, today announced the pricing of an underwritten public offering of 7,400,000 shares of its common stock at a public offerin |
|
| April 19, 2023 |
Marpai, Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Marpai, Inc. Announces Proposed Public Offering of Common Stock New York – April 14, 2023 – Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI) a technology company transforming the company health plan for employers that self-fund their healthcare, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of c |
|
| April 19, 2023 |
Underwriting Agreement, dated April 17, 2023, by and between Marpai, Inc. and ThinkEquity LLC Exhibit 1.1 UNDERWRITING AGREEMENT between MARPAI, INC. and THINKEQUITY LLC as Representative of the Several Underwriters MARPAI, INC. UNDERWRITING AGREEMENT New York, New York April 17, 2023 ThinkEquity LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 17 State Street, 22nd Fl New York, NY 10004 Ladies and Gentlemen: The undersigned, Marpai, Inc., a corporation |
|
| April 19, 2023 |
ThinkEquity The date of this prospectus supplement is April 17, 2023. Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-269326 PROSPECTUS SUPPLEMENT (To Prospectus dated January 30, 2023) 7,400,000 Shares Common Stock Marpai, Inc. We are offering 7,400,000 shares of our Class A common stock, $0.001 par value per share, or our common stock. Our common stock is traded on the Nasdaq Capital Market under the symbol “MRAI” On April 14, 2023, the las |
|
| April 19, 2023 |
Exhibit 4.1 Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 17, 2023 |
ThinkEquity The date of this prospectus supplement is April , 2023. Form 424(b)(5) Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the Appropriate Box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 29, 2023 |
Exhibit 21.1 LIST OF SUBSIDIARIES Company Name Jurisdiction of Incorporation Ownership Marpai Captive, Inc. Delaware 100% Marpai Administrators, LLC Florida 100% Marpai Health, Inc. Delaware 100% EYME Technologies, Ltd. Israel 100% Maestro Health, LLC Delaware 100% |
|
| March 29, 2023 |
Exhibit 10.31 MARPAI, INC. February 23, 2023 Mr. Lutz Finger VIA E-MAIL Dear Lutz: 1. You and Marpai, Inc. (the “Company”) are parties to an Employment Letter Agreement effective February 28, 2022 (the “Employment Agreement”). This letter (this “Amendment”) modifies the Employment Agreement as set forth below: 1.1 Section 10(a) is deleted in its original form and is replaced by the following sente |
|
| March 29, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS THE Fourth QUARTER and YEAR END 2022 RESULTS 54% Increase in revenue in THE FOURTH Quarter 2022 versus THIRD QUARTER 2022 New York, March 29, 2023—Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), a technology company transforming the company health plan for employers that self-fund their healthcare, today reported financial results fo |
|
| March 29, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40904 |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 01, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 7, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Marpai Hires Gonen Antebi as Chief Operating Officer Seasoned healthtech leader with a track of profitable growth to lead Company’s TPA businesses NEW YORK, Feb. 7, 2023 /PRNewswire/ - Marpai, Inc. ("Marpai" or the "Company") (Nasdaq: MRAI), an AI-technology company transforming self-funded employer health plans, has hired Gonen Antebi as its Chief Operating Offi |
|
| February 1, 2023 |
| MarpaiHealth.com (NASDAQ: MRAI) Company Presentation February 2023 Exhibit 99.1 | 2 Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as am |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 01, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 1, 2023 |
Exhibit 10.1 Marpai, Inc. January 31, 2023 Mr. Gonen Antebi Via electronic mail Dear Gonen: Marpai, Inc. (the “Company”) is pleased to offer you employment on the following terms: 1. Position; Start Date. Your title will be Chief Operating Officer, and you will report to the Company’s Chief Executive Officer. This is a full-time position. While you render services to the Company, you will not enga |
|
| January 26, 2023 |
Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 January 26, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: Marpai, Inc. (CIK: 0001844392) Registration Statement No. 333-269326 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: DarioHealth Corp. (the “Registrant”) hereby reque |
|
| January 20, 2023 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) Marpai, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be |
|
| January 20, 2023 |
As filed with the Securities and Exchange Commission on January 20, 2023 Table of Contents As filed with the Securities and Exchange Commission on January 20, 2023 Registration No. |
|
| January 13, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| January 10, 2023 |
The accompanying notes are an integral part of these consolidated financial statements. Exhibit 99.1 Maestro Health, LLC. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2021 and 2020 Mazars USA LLP is an independent member firm of Mazars Group. Maestro Health, LLC. and Subsidiaries Table of Contents December 31, 2021 and 2020 Page(s) Independent Auditor’s Report 1-2 Consolidated Balance Sheets 3-4 Consolidated Statements of Operations 5 Consolidated State |
|
| January 10, 2023 |
The accompanying notes are an integral part of these consolidated financial statements. Exhibit 99.2 Maestro Health, LLC. and Subsidiaries Consolidated Financial Statements Nine Months Ended September 30, 2022 (Unaudited) Maestro Health, LLC. and Subsidiaries Table of Contents September 30, 2022 Page(s) Independent Auditors’ Review Report 1 Consolidated Balance Sheets 2 Consolidated Statements of Operations 4 Consolidated Statement of Members’ Deficit 5 Consolidated Statements of Cas |
|
| January 10, 2023 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 10, 2023 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Introduction The following unaudited pro forma condensed combined financial information is based on the historical consolidated financial statements of Marpai, Inc. (“Marpai”) and Maestro Health, LLC (“Maestro”), after giving effect to Marpai’s acquisition of Maestro. The notes to the unaudited pro forma condensed combined f |
|
| December 22, 2022 |
December 2022 Company Presentation | MarpaiHealth.com (NASDAQ: MRAI) Exhibit 99.1 | 2 Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc. (the ?Company?) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as am |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 9, 2022 |
MARPAI, INC. REPORTS THIRD QUARTER 2022 RESULTS EX-99.1 2 mrai-ex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS THIRD QUARTER 2022 RESULTS New York, November 9, 2022—Marpai, Inc. (“Marpai” or the “Company”) (Nasdaq: MRAI), an AI-technology company transforming the $22 billion Third-Party Administrator (TPA) market supporting self-funded employer health plans, today reported financial results for the third quarter ended |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40904 “ MARPAI, INC. ( |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| November 1, 2022 |
EX-99.1 2 mrai-ex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Marpai Announces Closing of the Acquisition of Maestro Health The acquisition doubles Marpai’s size, expands the reach of AI-powered health services, adds pharmacy cost containment and clinical care programs to its platform NEW YORK, November 1, 2022 — Marpai, Inc. (Nasdaq: MRAI) (“Marpai” or the “Company”), a technology company t |
|
| November 1, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 01, 2022 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| October 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2022 MARPAI, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40904 86-1916231 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| October 14, 2022 |
EX-99.1 2 mrai-ex991.htm EX-99.1 October 2022 | MarpaiHealth.com (NASDAQ: MRAI) Company Presentation Exhibit 99.1 | 2 Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc. (the “Company”) related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S |
|
| August 29, 2022 |
US5713541093 / MARPAI INC / Lamendola Damien - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 (646) 303-3483 (Name, Addres |
|
| August 25, 2022 |
EX-99.1 2 tm2224526d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Marpai Launches MarpaiRx Pharmacy Benefit Management Solution to Decrease Prescription Costs New innovative PBM lowers drug costs for self-insured health plans and makes it easy for members to find affordable medications NEW YORK, August 25, 2022 — Marpai, Inc., (“Marpai”) (Nasdaq: MRAI), an AI technology company transforming third-party ad |
|
| August 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File N |
|
| August 23, 2022 |
US5713541093 / MARPAI INC / Lamendola Damien - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 (646) 303-3483 (Name, Addres |
|
| August 15, 2022 |
Table of Contents` ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporatio |
|
| August 10, 2022 |
MARPAI, INC. REPORTS SECOND QUARTER 2022 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS SECOND QUARTER 2022 RESULTS New York, August 10, 2022?Marpai, Inc. (?Marpai? or the ?Company?) (Nasdaq: MRAI), an AI-technology company transforming the $22 billion Third-Party Administrator (TPA) market supporting self-funded employer health plans, today reported financial results for the second quarter ended June 30, 2022. The Company?s con |
|
| August 9, 2022 |
Exhibit 10.1 EXECUTION VERSION PURCHASE AGREEMENT by and between X.L. AMERICA, INC., SEAVIEW RE HOLDINGS INC., AXA S.A. and MARPAI, INC. dated as of August 4, 2022 for the purchase of MAESTRO HEALTH, LLC TABLE OF CONTENTS Page ARTICLE I DEFINITIONS; CONSTRUCTION 1 Section 1.1 Definitions 1 Section 1.2 Construction 13 Section 1.3 Disclosure Schedule 14 ARTICLE II SALE AND TRANSFER OF UNITS; PURCHAS |
|
| August 9, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Nu |
|
| August 9, 2022 |
A u g u s t 2 0 2 2 (NASDAQ: MRAI) | MarpaiHealth.com Company Presentation Exhibit 99.1 A u g u s t 2 0 2 2 (NASDAQ: MRAI) | MarpaiHealth.com Company Presentation Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc . (the ?Company?) related thereto contain or may contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities law |
|
| August 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Nu |
|
| August 4, 2022 |
Marpai To Acquire Maestro Health Approximately Doubling Its Size Exhibit 99.1 Marpai To Acquire Maestro Health Approximately Doubling Its Size NEW YORK, August 4, 2022 /PRNewswire/ - Marpai, Inc. (?Marpai? or the ?Company?) (Nasdaq: MRAI), an AI-technology company transforming the $22 billion Third-Party Administrator (TPA) market supporting self-funded employer health plans, today announced it has signed a definitive agreement to acquire Maestro Health (?Maest |
|
| August 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Nu |
|
| June 14, 2022 |
As filed with the Securities and Exchange Commission on June 14, 2022 As filed with the Securities and Exchange Commission on June 14, 2022 Registration No. |
|
| June 14, 2022 |
EX-FILING FEES 4 tm2218273d1ex-filligfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Marpai, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Amount Registered (1)(2) Proposed Maximum Offering Price Per Share (3) Proposed Maximum Aggregate Offering Price Fee Rate Amou |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporation) |
|
| May 13, 2022 |
May 2022 MarpaiHealth.com Company Presentation (NASDAQ: MRAI) Exhibit 99.1 May 2022 MarpaiHealth.com Company Presentation (NASDAQ: MRAI) | 2 Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc . (the ?Company?) related thereto contain or may contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws, as ame |
|
| May 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporation) |
|
| May 11, 2022 |
Table of Contents` ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporation) |
|
| May 11, 2022 |
MARPAI, INC. REPORTS FIRST QUARTER 2022 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS FIRST QUARTER 2022 RESULTS New York, May 11, 2022?Marpai, Inc. (?Marpai? or the ?Company?) (Nasdaq: MRAI), an AI-technology company transforming the $22B Third-Party Administrator (TPA) market supporting self-funded employer health plans, today reported financial results for the first quarter ended March 31, 2022. The Company?s consolidated r |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the Appropriate Box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporation) |
|
| April 7, 2022 |
April 2022 MarpaiHealth.com Company Presentation Exhibit 99.1 April 2022 MarpaiHealth.com Company Presentation | 2 Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc . (the ?Company?) related thereto contain or may contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws, as amended . Statem |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporation |
|
| March 31, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE MARPAI, INC. REPORTS THE Fourth QUARTER and YEAR END 2021 RESULTS 23% Increase in revenue in THE FOURTH 2021 versus THIRD QUARTER 2021 New York, March 30, 2022?Marpai, Inc. (?Marpai? or the ?Company?) (Nasdaq: MRAI), an AI-technology company transforming the $22B Third-Party Administrator (TPA) market supporting self-funded employer health plans, today reported f |
|
| March 30, 2022 |
? Exhibit 10.30 MARPAI, INC. ? Mr. Lutz Finger Via electronic mail ? Dear Lutz: Marpai, Inc. (the ?Company?) is pleased to offer you employment on the following terms: 1.Position; Start Date. Your initial title will be President ? Product and Development, and you will initially report to the Company?s Chief Executive Officer. This is a full-time position. While you render services to the Company, |
|
| March 30, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 30, 2022 |
Exhibit 4.68 ? DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 30, 2022, Marpai, Inc., a Delaware corporation (?we,? ?our? and the ?Company?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: Class A Common Stock, par value $0.0001 per share. The following description of such se |
|
| March 30, 2022 |
? Exhibit 10.29 BrightMark Consulting, LLC 42 Harbor Avenue Westport, CT 06880 January 6, 2021 Marpai Health, Inc. 14 Todd Drive East Hampton, NY 11937 Dear Mr. Gonzalez: This letter agreement together with the exhibit attached hereto (collectively, the ?Agreement?) shall constitute the consulting/services agreement by and between BrightMark, LLC (?Consultant?) and Marpai Health, Inc. (?Client?). |
|
| March 30, 2022 |
List of Subsidiaries of the Company Exhibit 21.1 ? LIST OF SUBSIDIARIES ? ? ? ? ? ? ? Company Name Jurisdiction of Incorporation Ownership Marpai Captive, Inc. ? Delaware ? 100% ? Continental Benefits, LLC ? Florida ? 100% ? Marpai Health, Inc. ? Delaware ? 100% ? EYME Technologies, Ltd. ? Israel ? 100% ? ? |
|
| March 30, 2022 |
EX-10.14 3 mrai-20211231xex10d14.htm EX-10.14 Exhibit 10.14 AMENDMENT NO. 1 TO AMENDED AND RESTATED EXHIBIT A SERVICES AND COMPENSATION This Amendment No. 1 to the Amended and Restated Exhibit A (this “Amendment”) is entered into as of October 1, 2021 by Yaron Eitan (“Consultant”) and Marpai, Inc. (“Company”). The Amended and Restated Exhibit A to the Agreement, entitled Services and Compensation, |
|
| March 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporation |
|
| March 18, 2022 |
March 2022 MarpaiHealth.com Company Presentation Exhibit 99.1 March 2022 MarpaiHealth.com Company Presentation | 2 Forward Looking Statements This presentation and the statements of representatives and partners of Marpai, Inc . (the ?Company?) related thereto contain or may contain forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U . S . Federal securities laws, as amended . Statem |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporat |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporat |
|
| February 15, 2022 |
Exhibit 99.1 Marpai Announces Unaudited Fourth Quarter 2021 Revenues of $5.7 to $5.9 million Company also announced it ended 2021 with cash and cash equivalents (excluding restricted cash) of $19.2 million NEW YORK, Feb. 15, 2022 /PRNewswire/ - Marpai, Inc. ("Marpai" or the "Company") (NASDAQ: MRAI), a deep learning technology company transforming third party administration (TPA) in the self-funde |
|
| February 1, 2022 |
MRAI / Marpai Inc Class A / Lamendola Damien - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 (646) 303-3483 (Name, Addres |
|
| February 1, 2022 |
MRAI / Marpai Inc Class A / Lamendola Damien - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Damien Lamendola c/o Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 (646) 303-3483 (Name, Address and Telephone Nu |
|
| January 24, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2022 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporati |
|
| January 24, 2022 |
Exhibit 99.1 marpaihealth.com SMART Technology Transforming Health Plan Administration Company Presentation January 2022 | 2 Forward Looking Statements The Company filed a registration statement on Form S - 1 , as amended (Registration No .: 333 - 258029 ) (the ?Registration Statement?) with the Securities and Exchange Commission for its initial public offering of shares of class A common stock wh |
|
| December 30, 2021 |
MRAI / Marpai Inc Class A / Gonzalez Edmundo - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Edmundo Gonzalez c/o Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 (646) 303-3483 (Name, Address and Telephone Nu |
|
| December 21, 2021 |
MRAI / Marpai Inc Class A / David Eli - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Eli David c/o Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 (646) 303-3483 (Name, Address and Telephone Number of |
|
| December 21, 2021 |
MRAI / Marpai Inc Class A / EITAN YARON - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MARPAI, INC. (Name of Issuer) Class A Common stock, $0.0001 par value (Title of Class of Securities) 571354 109 (CUSIP Number) Yaron Eitan c/o Marpai, Inc. 5701 East Hillsborough Ave., Suite 1417 Tampa, Florida 33610-5428 (646) 303-3483 (Name, Address and Telephone Number |
|
| December 20, 2021 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2021 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporat |
|
| December 20, 2021 |
MARPAI, INC. INSIDERS BUY $1.1 million of COMMON STOCK Exhibit 99.1 MARPAI, INC. INSIDERS BUY $1.1 million of COMMON STOCK december 20, 2021 New York, NY-(BUSINESS WIRE)?Marpai, Inc. (?Marpai? or the ?Company?) (NASDAQ: MRAI), a deep learning technology company transforming third party administration (TPA) in the self-funded health insurance market, today announced the Company?s management and directors purchased $1.1 million of Marpai common stock. O |
|
| December 14, 2021 |
Table of Contents` ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 14, 2021 |
Exhibit 10.1 ? EXECUTION VERSION ? AGREEMENT FOR CONVERSION ? OF ? SECURED CONVERTIBLE PROMISSORY NOTE ? This AGREEMENT FOR CONVERSION OF SECURED CONVERTIBLE PROMISSORY NOTE (this ?Conversion Agreement?), is made and entered into as of this 26111 day of October 2021 (the ?Effective Date?), by and between Marpai, Inc. a Delaware corporation (the ?Company?), and SQN Venture Income Fund, LP (the ?Hol |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form N-SAR o Form N-CSR For Period Ended: September 30, 2021 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on Form N-SAR For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| December 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporati |
|
| December 9, 2021 |
EX-99.1 2 tm2134918d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 MARPAI, INC. REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS 22% Increase in revenue in q3 2021 versus tHE SECOND QUARTER OF 2021 company PROVIDES 2021 FOURTH QUARTER REVENUE GUIDANCE OF $5.6M-$5.8M december 9, 2021 New York, NY-(BUSINESS WIRE)—Marpai, Inc. (“Marpai” or the “Company”) (NASDAQ: MRAI), a deep learning technology company transfor |
|
| November 16, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 MARPAI, INC. (Exact name of registrant as specified in its charter) 001-40904 (Commission File Number) Delaware 86-1916231 (State or other jurisdiction of incorporat |
